Alogliptin(all oh glip’ tin)
Nesina
PREGNANCY CATEGORY B
Drug Classes
Antidiabetic
Dipeptidyl peptidase-4 (DPP4) inhibitor
Therapeutic Actions
Slows inactivation of the incretin hormones by DPP4, increasing these hormone levels and prolonging their activity. The incretin hormones stimulate insulin release in response to a meal and help regulate glucose homeostasis throughout the day. This increases and prolongs insulin release and reduces hepatic glucose production to help achieve glycemic control.
Indications
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Contraindications and Cautions
Contraindicated with history of serious hypersensitivity reactions to alogliptin.
Use cautiously with hepatic impairment, pregnancy, lactation.
Available Forms
Tablets—6.25, 12.5, 25 mg
Dosages
Adults
25 mg PO once a day without regard to food.
Pediatric patients
Safety and efficacy not established.
Patients with renal impairment
CrCl 30 to less than 60 mL/min, 6.25 mg/day PO; CrCl 15 to less than 30 mL/min, 12.5 mg/day PO.
